MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate In A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
<=TUDY NUMBER: 
CONTINUATION: page _3_ of JJ. pages. 
contaminating the harvested bone marrow and blood could cause 
relapse, but the chance of relapse has not been found to be 
higher in patients given back marrow containing many tumor 
cells as compared to marrow containing no visible tumor cells. 
It may be that tumor cells do not survive the transplant 
procedure as well as normal cells. 
We will now describe each step in this treatment plan. 
1) Pre-transplant testing: To enter this study you will need 
to have many blood, urine and x-ray tests to determine the 
extent of your tumor and the condition of your bone marrow, 
kidneys and liver. You will be tested for viruses which could 
make the transplant procedure more dangerous. You will also 
need to have special breathing tests and heart tests to make 
sure these vital organs are in condition to undergo bone 
marrow transplantation. A bone marrow aspiration and biopsy 
will be done to make sure you have enough cells to allow a 
good harvest, and to check for tumor cells. 
2) Central line placement: In the operating room under 
general or local anesthesia special intravenous tubing called 
a Hickman catheter will be inserted under your skin into a 
large vein in your chest or neck. The risks of this procedure 
include bleeding and * pain at the insertion site and very 
rarely collapse of a lung during the procedure. This line is 
necessary for frequent blood drawing, harvesting of peripheral 
blood stem cells, and for the administration of all the 
medicines and blood products you will need during the 
transplant. 
3) Peripheral Blood Stem Cell Harvest: At least one month 
after your last chemotherapy or radiation treatment, you will 
be admitted to the hospital and you will be given a single 
intravenous dose of a chemotherapeutic drug called 
cyclophosphamide. You will also be given 4 intravenous doses 
of a drug called MESNA that protects your urinary bladder from 
the damage cyclophosphamide can cause. The next day you will 
be started on a drug called G-CSF (granulocyte colony- 
stimulating factor) given by injections under the skin. The 
cyclophosphamide and the G-CSF stimulate the bone marrow to 
release "stem cells" into the circulating blood where they can 
be collected by a procedure called pheresis. 
Cyclophosphamide can cause fever, low blood counts, hair loss, 
1 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2S14-1 (10-84) 
[72] 
Recombinant DNA Research, Volume 16 
